CMS approves coverage for Dexcom G6 CGM, the only CGM system recognized by Medicare that offers mobile device compatibility and no fingerstick calibration
SAN DIEGO–(BUSINESS WIRE)–Oct. 18, 2018-- DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), announced today the new Dexcom G6® CGM System will be covered for Medicare beneficiaries, having met the category requirements for therapeutic CGM systems by the U.S. Centers for Medicare & Medicaid Services (CMS). Coverage for therapeutic CGM includes certain beneficiaries who have either Type 1 or Type 2 diabetes and intensively manage their insulin. The company expects to begin shipping product to Medicare customers in the first part of 2019.
“The Dexcom G6 is a game-changer for people with diabetes, and we are thrilled to provide this innovative technology to the many Americans with diabetes who rely on Medicare,” said Kevin Sayer, President and CEO of Dexcom. “With the CMS policy coverage, Medicare beneficiaries with diabetes who use G6 will no longer require fingersticks to make treatment decisions or calibrate their CGM.”
The new Dexcom G6 boasts a number of features that make it a very powerful diabetes management tool.
- Zero fingersticks – No fingersticks needed for calibration or diabetes treatment decisions
- One-touch applicator – Redesigned one-touch applicator that is virtually painless
- Low-profile wearable – New transmitter with a 28 percent lower profile for comfortable wear
- Mobile compatibility – Compatibility with smart device apps to display and share glucose information with up to five people
- Alerts and alarms – Customizable alerts and alarms to proactively warn users of pending dangerous high and low blood sugar levels
Who is covered?
According to CMS, therapeutic CGM may be covered by Medicare when all of the following criteria are met:
- The beneficiary has diabetes mellitus; and,
- The beneficiary has been using a home blood glucose monitor (BGM) and performing frequent (four or more times a day) BGM testing; and,
- The beneficiary is insulin-treated with multiple daily injections (MDI) of insulin or a continuous subcutaneous insulin infusion (CSII) pump; and,
- The beneficiary’s insulin treatment regimen requires frequent adjustment by the beneficiary on the basis of therapeutic CGM testing results; and,
- In six (6) months prior to ordering the CGM, the beneficiary had an in-person visit with the treating practitioner to evaluate their diabetes control and determine that the above criteria are met; and,
- Every six (6) months following the initial prescription of the CGM, the beneficiary has an in-person visit with the treating practitioner to assess adherence to their CGM regimen and diabetes treatment plan.
How to get the Dexcom G6? It’s easy.
- New customers of Dexcom can get started today with Dexcom G5 Mobile by going to http://www.dexcom.com/medicare-coverage.
- Once G6 is available, Dexcom will be reaching out to current Medicare G5 customers when their transmitter is eligible to be replaced.
- Dexcom will also discuss the G6 and the Medicare beneficiary’s eligibility during routine monthly contact.